Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$438.9M
-5.9% from 2023
Prescriptions
25K
$17,719.22 per claim
Patients
4,465
3,510 prescribers
Total spending, 2024
$438.9M
$98,298.98 per patient
Medicare prescription drug plans paid $438.9M for Inlyta in 2024, for 24,770 prescriptions and refills to 4,465 patients (down 5.9% from 2023). The average cost per claim was $17,719.22.
Texas had the highest Medicare cost for Inlyta in 2024: $49.9M for 2,746 claims, followed by California ($44.0M).
Hans J Hammers, medical oncology in Dallas, TX, had the highest Medicare cost for Inlyta in 2024: 103 claims costing $2.0M.
Inlyta is made by Pfizer Inc. (PFE), listed in the Medicare spending data as Pfizer US Pharm.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Hans J Hammers Dallas, TX | Medical Oncology | 103 | 11 | $2.0M |
| Moshe C Ornstein Cleveland, OH | Hematology-Oncology | 93 | 16 | $2.0M |
| Adanma Anji Ayanambakkam Attanathi |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 3,586 | 24,578 | 4,737 | $417.6M |
| 2023 | 3,602 | 25,232 | 4,733 | $466.6M |
| 2024 | 3,510 | 24,770 | 4,465 | $438.9M |
Amount reimbursed by state Medicaid programs, all states
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Hematology-Oncology |
| 105 |
| 18 |
| $1.9M |
| Fern M Anari Philadelphia, PA | Medical Oncology | 98 | 15 | $1.9M |
| Maria C Aloba El Paso, TX | Hematology-Oncology | 76 | 14 | $1.4M |
| Mehmet A Bilen Atlanta, GA | Hematology-Oncology | 79 | Under 11 | $1.2M |
| Zita D Lim Houston, TX | Physician Assistant | 57 | Under 11 | $1.2M |
| Aihua E Yen Houston, TX | Hematology-Oncology | 58 | Under 11 | $1.2M |
| Gautam G Jha Minneapolis, MN | Hematology-Oncology | 70 | Under 11 | $1.1M |
| Santa M Merle Guaynabo, PR | Hematology-Oncology | 93 | Under 11 | $1.0M |
| Joseph I Clark Maywood, IL | Hematology-Oncology | 69 | 12 | $1.0M |
| Meredith A Morgan Nashville, TN | Nurse Practitioner | 60 | Under 11 | $989K |
| Kathryn E Beckermann Franklin, TN | Hematology-Oncology | 52 | Under 11 | $984K |
| Ines J Sanchez-Rivera El Paso, TX | Medical Oncology | 48 | Under 11 | $972K |
| Thomas B Sneed Little Rock, AR | Hematology-Oncology | 45 | Under 11 | $948K |
| Rahul Ravilla Albany, NY | Hematology-Oncology | 46 | Under 11 | $926K |
| Eduardo Miranda Laredo, TX | Hematology-Oncology | 48 | Under 11 | $886K |
| Michael J McCormack Jr. Winston Salem, NC | Hematology-Oncology | 47 | Under 11 | $857K |
| Daniel M Geynisman Philadelphia, PA | Hematopoietic Cell Transplantation and Cellular Therapy | 53 | Under 11 | $853K |
| Ana C Adriazola Houston, TX | Nurse Practitioner | 41 | Under 11 | $841K |
| Jennifer L Heins Westwood, KS | Physician Assistant | 47 | Under 11 | $830K |
| Susan M Sargent Rochester, NY | Nurse Practitioner | 44 | Under 11 | $802K |
| Sarah Mizelle Tampa, FL | Physician Assistant | 39 | Under 11 | $797K |
| Arnab Basu Jacksonville, FL | Hematology-Oncology | 55 | Under 11 | $791K |
| Marc D Michaelson Boston, MA | Hematology-Oncology | 39 | Under 11 | $783K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Pfizer US Pharm PFE | 24,770 | $438.9M |